Eli Lilly Launches New Program to Enhance Obesity Drug Coverage

Written by Emily J. Thompson, Senior Investment Analyst

Source: CNBC

Updated: 1 hour ago

0mins

LLY-0.41%

NVO+5.02%

CVS+0.1%

Should l Buy LLY?

Source: CNBC

Program Launch: Eli Lilly has introduced the 'Employer Connect' platform aimed at helping more employers cover obesity drugs, addressing a major barrier to patient access and expected to enhance employee drug accessibility.
Price Transparency: Through this platform, employers can purchase a multi-dose form of Zepbound at a net discounted price of $449 per month, avoiding traditional rebate models, thereby providing clearer visibility on drug pricing for employers.
Flexible Benefits Design: Employers can choose from 15 different third-party administrators to design benefits tailored to their budget and workforce needs, offering comprehensive obesity management services including telehealth, nutrition, and lifestyle support.
Government Insurance Coverage: Under landmark deals with President Trump, Medicare will cover obesity drugs for the first time, which is expected to further expand drug accessibility and benefit more patients.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on LLY

Wall Street analysts forecast LLY stock price to rise

20 Analyst Rating

18 Buy

2 Hold

0 Sell

Strong Buy

Current: 1007.730

Low

950.00

Averages

1192

High

1500

Current: 1007.730

Low

950.00

Averages

1192

High

1500

BofA

Buy

maintain

2026-02-24

Reason

BofA

Price Target

AI Analysis

2026-02-24

maintain

Buy

Reason

BofA says that today's announcement that Novo Nordisk (NVO) plans to slash GLP-1 list prices offers a flashy headline, but in the firm's view the update is unlikely to have any material impact on the U.S. market. BofA sees today's move as an attempt to reduce copay/coinsurance costs to patients in settings where that figure is calculated of list/WAC price. More broadly, the firm thinks it's fair for investors to wonder if/when commercial reimbursement of GLP-1's could become more commonplace, with BofA channel checks suggesting this may may hinge on convergence of PBM price and consumer cash price. Taken in aggregate, the firm sees limited impact to Eli Lilly's (LLY) GLP-1 franchise given no clear indication Novo is moving more aggressively on lower net pricing in the commercial insurance channel, greater anticipated contribution from cash pay and U.S. government channels which are unimpacted by today's update. BofA maintains a Buy rating on Eli Lilly.

RBC Capital

Outperform

initiated

$1,250

2026-02-24

Reason

RBC Capital

Price Target

$1,250

2026-02-24

initiated

Outperform

Reason

RBC Capital initiated coverage of Eli Lilly with an Outperform rating and $1,250 price target. The firm sees the company's obesity franchise dominating through 2030. Why investor sentiment is largely positive, there "remains some nervousness on elevated expectations" and positioning risks as Lilly reapproaches a $1 trillion market cap, the analyst tells investors in a research note. RBC believes the consensus "materially undervalues" the company's "transformative catalysts on the horizon."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LLY

Unlock Now

About LLY

Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Eli Lilly Launches Zepbound® KwikPen® to Enhance Obesity Treatment Access

1 hour agoPRnewswire

Platform Launch: Eli Lilly has introduced the Employer Connect platform, aimed at collaborating with independent program administrators to provide flexible obesity management medication solutions, thereby improving access for over 100 million American adults and potentially enhancing healthcare coverage for obesity patients significantly.
Cost Reduction: The Zepbound® KwikPen® is priced at $449, and with flexible cost-sharing options, employers can offer more affordable obesity treatment to employees, which is expected to improve treatment adherence and overall health outcomes among the workforce.
Clinical Trial Results: In the SURMOUNT-1 trial, adults taking Zepbound 15mg lost an average of 20.9% of their body weight over 72 weeks, compared to just 3.1% in the placebo group, demonstrating the drug's significant efficacy in obesity management, which could drive its widespread adoption in the market.
Strong Market Demand: Zepbound was the most prescribed weight management medication in the U.S. in 2025, and with FDA approval, it is expected to further increase its market share in obesity treatment, addressing the growing patient demand effectively.

Eli Lilly Launches Employer Connect Platform for Obesity Therapy Access

8 minutes agoseekingalpha

Platform Launch: Eli Lilly announced the launch of the Employer Connect platform, enabling employees to access its obesity therapy Zepbound at a lower cost, marking an innovative step in employee health management.
Collaborative Network: The platform will connect with over 15 independent program administrators, including Teladoc and GoodRx, as well as pharmacies like HealthDyne and CenterWell, enhancing drug accessibility and potentially increasing market penetration.
Pricing Strategy: Zepbound will be sold in a single-patient delivery device called KwikPen at a discounted price of $449 per dose, with final costs varying based on pharmacy and program administrator choices, which may impact employer cost control.
Strategic Implications: By breaking down barriers associated with traditional benefit designs, Eli Lilly aims to lower treatment obstacles and provide employers with greater control over employee access to obesity care, further solidifying its leadership position in the GLP-1 drug market.

Eli Lilly Launches Employer Connect Platform to Enhance Obesity Treatment Access

16 minutes agoNASDAQ.COM

Platform Launch: Eli Lilly's newly introduced Employer Connect platform aims to enhance access to obesity management treatments for employees, particularly as insurance coverage remains inconsistent for over 100 million American adults affected by obesity.
Addressing Coverage Gaps: The platform connects employers to independent program administrators and cost-sharing solutions, enabling employees to access prescribed treatments at reduced out-of-pocket costs, thereby alleviating financial barriers for obesity patients.
Partner Network: The platform launches with over 15 independent administrators and a nationwide pharmacy network, including Teladoc Health and GoodRx, ensuring that Lilly's obesity medication Zepbound KwikPen is available at a discounted price of $449 through network pharmacies.
Drug Indications: Zepbound is approved for adults with obesity and overweight adults with at least one weight-related medical condition, as well as certain patients with obstructive sleep apnea, highlighting Lilly's strategic positioning in the obesity treatment market.

Eli Lilly Launches New Platform to Improve Access to Obesity Medications

18 minutes agoBenzinga

Solution for Obesity: Eli Lilly's launch of the Employer Connect platform targets the approximately half of commercially insured American employees lacking access to obesity medications, addressing an economic burden exceeding $1.7 trillion annually due to obesity-related costs.
Platform Partnerships: The platform collaborates with over 15 independent program administrators, including pharmacies like HealthDyne and CenterWell, ensuring nationwide drug availability and enhancing employee access to medications.
Zepbound Pricing Strategy: Lilly's Zepbound KwikPen is priced at $449 across all doses, although final costs for employers and employees will vary based on the chosen administrator and cost-sharing model, potentially lowering out-of-pocket expenses for employees.
Clinical Trial Demand Support: In the SURMOUNT-1 trial, adults using Zepbound lost an average of 20.9% of body weight over 72 weeks compared to just 3.1% for the placebo group, demonstrating the drug's effectiveness in obesity management and further driving market demand.